

2nd Quarter 2019 Sales			
\$20.6B	Worldwide Decreased ▼	Excluding acquisitions/ divestitures on an operational basis	Worldwide Increased ▲
	(1.3)%		3.7%*
Diluted Earnings Per Share		Adjusted Diluted Earnings Per Share*	
\$2.08	Increased ▲	\$2.58	Increased ▲
	43.4%		22.9%




Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

“We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses. Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world.”

\$3.5
Billion

Worldwide Consumer Sales


Consumer worldwide sales increased: 1.2%
Primary contributors to growth:



\$10.5
Billion

Worldwide Pharmaceutical Sales


Pharmaceutical worldwide sales increased: 1.7%
Primary contributors to growth:



\$6.5
Billion

Worldwide Medical Devices Sales

Medical Devices worldwide sales decreased: (6.9)%
Primary contributors to growth:



Electrophysiology



Energy



Endocutters



Cerenovus



Sports

Note: values may have been rounded

For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on July 16, 2019, available at <http://www.investor.jnj.com/sales-earnings.cfm>.

*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson earnings release issued on July 16, 2019, as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.